The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g Vct5 Regulatory News (MIG5)

Share Price Information for Maven I&g Vct5 (MIG5)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.40
Bid: 29.40
Ask: 31.40
Change: 0.00 (0.00%)
Spread: 2.00 (6.803%)
Open: 30.40
High: 30.40
Low: 30.40
Prev. Close: 30.40
MIG5 Live PriceLast checked at -
Maven Income and Growth VCT 5 is an Investment Trust

To invest in a diversified portfolio of later-stage UK private companies to provide long-term capital appreciation and generate maintainable levels of income for shareholders.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

10 Aug 2021 16:31

RNS Number : 2056I
Maven Income and Growth VCT 5 PLC
10 August 2021
 

Maven Income and Growth VCT 5 PLC

 

Interim Results for the Six Months Ended 31 May 2021 (Unaudited)

 

The Directors announce the Chairman's Statement, Investment Manager's Interim Review and the unaudited Financial Statements for the six months ended 31 May 2021.

 

Highlights

 

• NAV total return at 31 May 2021 of 83.09p per share

 

• NAV at 31 May 2021 of 38.54p per share

 

• Increased interim dividend of 0.60p per share declared

 

• Offer for Subscription fully subscribed raising £20 million

 

Overview

On behalf of your Board, I am pleased to present the results for the six months to 31 May 2021. The reporting period has been dominated by the COVID-19 pandemic, as second wave of infection hit the UK in the Autumn, resulting in the reintroduction of protective measures and a further nationwide lockdown. It is, nevertheless, encouraging to report that, despite the challenging market conditions, your Company has made positive progress and is reporting a 4.1% increase in NAV total return to 83.09p per share, compared to 79.83p per share at the previous year end. This strong performance reflects the increasing strength and diversity of the investee portfolio, where many private companies have continued to make tangible commercial progress. The AIM quoted portfolio also recorded an uplift in value, reflecting positive trading updates and share price appreciation across the portfolio. Against this backdrop, the Directors are pleased to declare an increased interim dividend of 0.60p per share.

 

Notwithstanding the challenges in the wider economy, your Board is encouraged by the progress that has been achieved in further growing and diversifying the portfolio, in line with your Company's long term investment objective. Throughout the first half of the year, the Manager has maintained a selective approach to new investment, continuing to favour those companies that operate in sectors with defensive characteristics, where the impact of the pandemic has been less pronounced. Many of these companies have maintained growth in line with their business plans and are now well positioned to continue to develop as the economy recovers. The Board is generally encouraged by the performance across the investee portfolio and believes that the balance of holdings between private and AIM quoted companies provides a strong platform for future growth in Shareholder value. A summary of the key portfolio developments can be found in the Investment Manager's Review.

 

A notable highlight of the reporting period was the completion of the £20 million fundraising, which closed early and was fully subscribed. This new capital provides your Company with sufficient liquidity to ensure that it can maintain the momentum in the investment rate by carefully expanding and further developing the portfolio. Despite the economic conditions, the Manager continues to see strong demand for growth capital and the Directors are reassured that Maven is well placed to source and transact attractive VCT qualifying investments in both private and AIM quoted companies.

 

Throughout the period under review, the Manager has fully adhered to all Government and local guidelines in relation to COVID-19, including swiftly migrating its regional offices and administration hub to a remote working model in March 2020. Your Company has maintained full operational capability throughout this period, with all third-party providers continuing to service your Company, either remotely or from a COVID-secure office environment.

 

Interim Dividend

In respect of the year ending 30 November 2021, an increased interim dividend of 0.60p per Ordinary Share will be paid on 10 September 2021 to Shareholders on the register at 13 August 2021. Since the Company's launch, and after receipt of this latest dividend, 45.15p per share will have been distributed in tax free dividends. It should be noted that the payment of a dividend reduces the NAV of the Company by the total cost of the distribution.

 

Dividend Policy

As Shareholders will be aware from recent Interim and Annual Reports, decisions on distributions take into consideration a number of factors including the availability of surplus revenue, the realisation of capital gains, the adequacy of distributable reserves and the VCT qualifying level, all of which are kept under close and regular review by the Board and the Manager.

 

The Board and the Manager have been giving consideration to establishing a dividend policy. Further to these discussions, it is the Board's intention that, subject to the considerations outlined above, it will where possible seek to pay an annual dividend that provides Shareholders with a yield of 5% of the NAV per share at the year end, in the current and future years.

 

The Directors would like to remind Shareholders that, as the portfolio continues to expand and a greater proportion of holdings are invested in young companies, which may take longer to reach maturity, distributions will be closely linked to realisation activity, whilst also reflecting the Company's requirement to maintain its VCT qualifying level. If larger distributions are required, as a consequence of exits, this could result in a corresponding reduction in NAV per share. However, your Board considers this to be a tax efficient means of returning value to Shareholders, whilst ensuring ongoing compliance with the requirements of the VCT legislation.

 

Dividend Investment Scheme (DIS)

Your Company operates a DIS, through which Shareholders may elect to have their dividend payments utilised to subscribe for new Ordinary Shares issued by the Company under the standing authority requested from Shareholders at Annual General Meetings.

 

Shareholders who wish to participate in the DIS in respect of future dividends, including the interim dividend due to be paid on 10 September 2021, should ensure that a DIS mandate or CREST instruction, as appropriate, is received by the Registrar (Link Group) in advance of 27 August 2021, this being the next dividend election date. The mandate form, terms & conditions and full details of the scheme and tax considerations are available from the Company's website at www.mavencp.com/migvct5. Election to participate in the DIS can also be made through the Registrar's share portal at www.signalshares.com. Shares issued under the DIS should qualify for initial VCT tax relief applicable for the tax year in which they are allotted, subject to an individual Shareholder's particular circumstances. If a Shareholder is in any doubt about the merits of participating in the DIS, or their own tax status, they should seek advice from a suitably qualified adviser.

 

Fund Raising

On 23 October 2020, your Company together with the board of Maven Income and Growth VCT PLC, launched joint Offers for Subscription in new Ordinary Shares for up to £20 million in aggregate (£10 million for each company), with a combined over-allotment facility of up to £20 million (£10 million for each company). On 30 March 2021, the Directors were pleased to announce that your Company's Offer was fully subscribed, including full utilisation of the over-allotment facility.

 

An allotment of 24,921,994 new Ordinary Shares in respect of the 2020/21 tax year completed on 2 March 2021, with a further 26,817,537 new Ordinary Shares allotted on 1 April 2021. The allotment of 2,071,074 Ordinary Shares for the 2021/22 tax year took place on 4 May 2021.

 

This additional liquidity will enable your Company to expand the portfolio by investing in ambitious, growth focused private and AIM quoted companies that operate across a range of market sectors, and which are capable of generating capital gains. It will also ensure that existing portfolio companies can continue to be supported through follow-on funding where there is an ongoing business case that merits support. Furthermore, the funds raised will allow your Company to maintain its share buy-back policy, whilst also spreading costs over a wider asset base in line with the objective of maintaining a competitive total expense ratio for the benefit of all Shareholders.

 

Share Buy-backs

Shareholders have given the Board authority to buy back shares for cancellation or to be held in treasury, subject always to such transactions being in the best interests of Shareholders. During the period under review, 1,200,000 shares were bought back at a total cost of £465,000.

 

It is intended that, subject to market conditions, available liquidity and the maintenance of the Company's VCT status, shares will continue to be bought back at prices representing a discount of between 10% and 15% to the prevailing NAV per share.

 

Principal and Emerging Risks and Uncertainties

The principal and emerging risks and uncertainties facing the Company were set out in full in the Strategic Report contained within the 2020 Annual Report, and are the risks associated with investment in small and medium sized unlisted and AIM/AQSE quoted companies which, by their nature, carry a higher level of risk and are subject to lower liquidity than investments in larger quoted companies. The valuation of investee companies may be affected by economic conditions, the credit environment and other risks including legislation, regulation, adherence to VCT qualifying rules and the effectiveness of the internal controls operated by the Company and the Manager. These risks and procedures are reviewed regularly by the Audit and Risk Committees and reported to your Board. The Board has confirmed that all tests, including the criteria for VCT qualifying status, continue to be monitored and met.

 

In March 2020, the COVID-19 pandemic developed from being an emerging risk to a principal risk that had implications for the Company, the Manager, investee companies and both the UK and global economies. The Board and the Manager have sought to identify all of the individual risks associated with the pandemic that could impact on the Company, and the steps that are required to mitigate them. These have been recorded in separate risk registers that will be reviewed on a regular basis as the situation continues to evolve.

 

Regulatory Update

The EU (Future Relationship) Act 2020, which was agreed with the EU on 24 December 2020, came into effect on 1 January 2021. The potential impact of the UK's withdrawal from the EU has been closely monitored across the investee portfolio and, as at the date of this Interim Report, there is nothing material to report. The majority of investee companies have limited direct exposure to the EU, and those that do have been implementing contingency plans to mitigate any potential impact.

 

During the period under review, there have been no further amendments to the rules governing VCTs. The Spring Budget was delivered on 3 March 2021, with no changes proposed to the legislation governing VCTs.

 

The Directors and the Manager continue to apply the International Private Equity and Venture Capital (IPEV) Valuation Guidelines as the central methodology for all private company valuations. On 31 March 2020, the IPEV Guidelines Board issued Coronavirus Special Valuation Guidance to assist managers who are applying the IPEV Valuation Guidelines to their portfolios. The Guidelines are the prevailing framework for fair value information in the private equity and venture capital industry.

 

Environmental, Social and Governance (ESG)

The Board recognises the importance of ESG principles and believes that each portfolio company should behave responsibly towards the environment and society, whilst operating in line with governance best practice. The Directors are pleased to report that the Manager considers ESG matters as part of the investment appraisal process and ensures that any issues are identified at an early stage. The Manager is also developing a robust framework that will ensure ESG matters are carefully managed throughout the period of investment. This includes close engagement with each portfolio company in relation to corporate governance practices and support for the management team in developing policies on the environment, community engagement, HR and employee relations, corporate governance and responsible product marketing.

 

The Directors are aware of the work that the Manager is undertaking to address the recommendations of the Task Force on Climate-related Financial Disclosures, which seek to address the material financial impacts of the global transition to a lower carbon economy. The Directors are satisfied that the Manager is taking the appropriate steps to address those requirements and will continue to monitor progress.

 

In May 2021, the Manager became a signatory to the internationally recognised Principles for Responsible Investment, demonstrating its commitment to include ESG in investment decision making and ownership. The Manager has also become a signatory to the Investing in Women Code, which aims to improve female entrepreneurs' access to tools, resources and finance, supporting diversity and inclusion in access to finance.

 

Maven Capital Partners UK LLP (Maven)

On 26 May 2021, Mattioli Woods plc announced that it had entered into a conditional agreement to acquire Maven, subject to satisfaction of certain conditions and the approval of Mattioli Woods' shareholders. All required approvals were subsequently granted, and the transaction completed on 1 July 2021.

 

Maven will operate as an independently managed subsidiary of Mattioli Woods, retaining its regional business model, people and brand in entirety. As a result, there will be no direct impact for Maven's VCT clients, Shareholders or investee companies. Mattioli Woods plc is one of the UK's leading providers of wealth management and financial planning services and Maven offers a highly complementary fit with its existing operations. Maven and Mattioli Woods share a common objective of continuing to expand the enlarged business under PLC ownership. Both businesses are well known to each other and there is strong cultural alignment, and a common focus on providing clients with the best possible service. Further details on Mattioli Woods can be found at www.mattioliwoods.com.

 

Your Board has confirmed that it considers this to be a positive step in the evolution of Maven and has received confirmation that Bill Nixon will remain as its Managing Partner and lead VCT fund manager, and further, there will be no material changes to Maven's staff, operations or access to capital. In terms of the management of your Company, the investment team and support staff providing company secretarial, accounting and administrative services will all continue to operate as before. The Board looks forward to continuing its positive relationship with the Maven team in pursuit of the Company's long term investment strategy.

 

Outlook

The Directors are encouraged by the performance that has been achieved in the first half of the financial year, with the successful completion of a £20 million fundraising and further progress in the expansion and development of the investee company portfolio. As the remaining COVID-19 restrictions are lifted, the Directors are optimistic that the economic recovery will continue. The near term strategic objective remains focused on further growth through the addition of a diverse range of attractive growth companies that are capable of generating sustained improvements in Shareholder value.

 

Graham Miller

Chairman

 

10 August 2021

 

Investment Manager's Interim Review

 

• Continued expansion and diversification of the portfolio through the addition of five new VCT qualifying private company holdings, with a further two investments completed after the period end

 

• Six new VCT qualifying AIM quoted investments added to the portfolio

 

• £2.58 million realised through private company and AIM quoted disposals

 

Overview

Despite the ongoing challenges in the wider economy, it is encouraging to report that your Company added eleven new VCT qualifying holdings to the portfolio, deploying £4.1 million of investor capital. Following several years of active investment, your Company now has exposure to a broad range of carefully selected growth businesses that operate in attractive market segments such as biotech, cyber security, data analytics, fintech and healthcare. The Manager believes that many of these companies will, over time, become attractive to a wide range of potential buyers that may be willing to pay a strategic premium at exit. Shortly after the reporting period end, your Company completed its first IPO of a private investee company with the successful flotation on AIM of GENinCode, which has delivered a significant uplift in value only one year after your Company first invested.

 

Over the past few years, the Manager has been carefully transitioning the portfolio to one focused on early stage, growth companies and, whilst many holdings are still relatively early in their stage of development, the Manager is encouraged by the progress that is being achieved. Across the portfolio, many companies are reporting the achievement of specific milestones, as set out at the time of original investment, and growth in recurring revenues, through the securing of new customers or contracts. This demonstrates that the investment approach adopted by the Manager is starting to yield results, and the objective for the second half of the year is to continue to grow and diversify the portfolio.

 

Maven's regional office network and strong presence in the key corporate finance territories continues to provide access to a wide range of potential opportunities, which enables the Manager to maintain a highly selective approach to new investment. The Manager will maintain this cautious stance and retains a preference for investing in companies that operate in sectors with defensive characteristics, and limited direct consumer exposure, or those that offer a disruptive technology or approach which is capable of scalable growth. Where possible, the Manager will invest alongside another VCT house or partner as a means of mitigating risk. This is particularly relevant when further funding rounds are anticipated, as it enables the Manager to continue to support an investee company without building a disproportionately large holding. Investments will generally be structured in tranches, with funding released progressively subject to the achievement of milestones. This ensures that both the Manager and investee management team are aligned in terms of growth expectations and strategic development.

 

Whilst the Manager is optimistic in the future potential of the portfolio, it is important to note that it may take time for some of these investee companies to achieve scale and for full value to be optimised. The timing of exits is difficult to predict, particularly for young companies where those that gain early commercial traction may attract interest from a strategic acquirer, whereas others may need to raise further capital over an extended period in order to develop to their full potential before a formal exit process can be initiated. Throughout the period of investment, Maven maintains an active relationship with each investee management team and is closely involved during an exit process or when an unsolicited approach is received. This market knowledge helps to ensure that shareholder returns are maximised.

 

Since the outbreak of the pandemic, the Manager has observed all Government advice and local guidelines, with the majority of its team continuing to work remotely. In line with guidance, the Maven offices have now re-opened and it is anticipated that the Maven team will commence a phased return to the regional offices once the restrictions are lifted, as the Manager values the importance of office based interaction and the benefits of collaborative working.

 

Portfolio Developments

 

Private Company Holdings

 

Despite the challenges presented by the pandemic, Bright Network, which has developed a media technology platform that enables leading employers to reach, identify and recruit high quality graduates and young professionals, has continued to make positive progress. In response to the first nationwide lockdown, Bright Network successfully pivoted its model from being focused on face-to-face interactions to one that could operate virtually. This allowed the business to continue to provide its range of graduate recruitment services, including events such as virtual careers fairs, where in-person events have been prohibited due to the restrictions on non-essential travel and mass gatherings. This transition has enabled the business to strengthen its market position, which means it is well placed to deliver future growth.

 

Throughout the period, e-commerce analytical software provider e.fundamentals continued to make progress and delivered further growth in annual recurring revenue (ARR). The business is focused on providing consumer brands with customer information to help them maximise their online listings and range of digital touchpoints used by shoppers, which has become increasingly important over the past year with the growing trend towards online shopping, particularly for grocery products. In recent months e.fundamentals has secured a number of new high profile clients including PepsiCo, to complement the existing client base that includes household names such as Dairy Crest, Kellogg's, Mars and Royal Canin. The business has a good pipeline of opportunities and the outlook for the remainder of 2021 is encouraging.

 

Horizon Ceremonies is trading to plan and in April 2021 opened its second crematorium in Cannock, Staffordshire. The management team are working with local funeral directors and undertakers to increase awareness of the facility, its service offerings and Horizon's family-orientated approach. Construction of a third crematorium, in the suburbs of Glasgow, is now well underway and the facility is expected to open in November 2021. Two further sites are now under option, with planning applications submitted. Trading at the original site in the Clyde Coast and Garnock Valley remains strong, and business practices will be replicated across the new facilities as they are opened. The medium-term strategic objective remains to build a portfolio of modern, technologically advanced crematoria that meet the best environmental standards and offer the best possible service for families, and to sell the business to a trade acquirer when the growth plan has been achieved.

 

Whilst market conditions within the hospitality sector have remained challenging following the second nationwide lockdown, QikServe has continued to experience good growth. The Edinburgh based business has developed a patented self-service platform that enables customers to order and pay for refreshments either at their table or remotely, without the need for personal contact or handling menus. Following the acquisition in 2019 of Preoday, a provider of order ahead, click & collect solutions, QikServe has been well positioned to benefit from the accelerated transition within the hospitality sector to digital ordering systems as a result of the pandemic. During the period, the business has expanded its client base and grown ARR, and it also has a strong pipeline of opportunities that should help to continue to deliver growth.

 

Rockar is a developer of a disruptive digital platform for buying new and used cars. During the period it has continued to grow its online white label software solution attracting the attention of a number of car manufacturers and national dealership groups that are keen to develop a digital alternative to replace or complement the traditional showroom model. Following the demerger of the retail business, Rockar is now exclusively focused on developing and expanding its technology platform. It is anticipated that there will be a progressive move towards digitising the retail car sales market, in line with the general trend across the retail economy and Rockar is at the forefront of this technology and ideally positioned to grow its presence.

 

Throughout the pandemic, The GP Service (GPS), which provides a secure end-to-end system that allows patients to consult with a doctor online and to have a private prescription dispensed by a local pharmacy through an electronic portal, has continued to make progress and has 1,600 pharmacy partners signed up and using the service. Whilst sales growth has slowed over recent months, as the impact of the pandemic has restricted the roll-out of the technology to high street pharmacy partners, the business model has diversified and now incorporates a corporate offering with several 'blue-chip' clients using GPS as an employee benefit. GPS is fully regulated by the Care Quality Commission and has applied to be part of the NHS New Digital Framework and remains at the forefront of this growing market.

 

In light of improved trading following the easing of lockdown restrictions, the protective provision that was taken at the start of the pandemic against the value of the holding in education safeguarding software provider eSafe was reversed. The reopening of schools and colleges for face-to-face learning, coupled with recent high profile child safeguarding cases, has highlighted the importance of having robust systems and protocols in place to protect children and young people, and eSafe's track record and reputation in this niche market has helped to deliver growth. During the period, an offer to acquire the business was received from Smoothwall, a private equity backed competitor. The sale completed shortly after the period end, generating a total return of 1.35 times cost over the life of the investment.

 

In response to the rapid change in operating conditions following the outbreak of COVID-19, GradTouch successfully pivoted to a digital model and recently completed a transformative acquisition, which adds significant scale and boosts its market presence. The enlarged business provides a strong platform for future growth that should be enhanced by the recovery in the graduate recruitment market.

 

A small number of portfolio companies have failed to deliver their commercial objectives, which was largely attributed to the challenging conditions in the wider economy resulting from the pandemic. Protective provisions have been taken against the value of holdings in: Lloyd's of London insurance brokering firm, Altra Consultants, which is taking longer than expected to achieve necessary scale; online boiler supplier, installer and service provider Boiler Plan which, despite making good early progress, has experienced increased levels of competition in its market; and DigitalBridge, a developer of virtual design and visualisation software that is taking longer than expected to secure commercial contracts.

 

Quoted Holdings

 

During the reporting period, the AIM quoted portfolio performed well, delivering a 37.7% return and outperforming the FTSE AIM All-Share Index, which increased by 17.9% over the same period.

 

The Manager was able to take advantage of the positive market dynamics and actively traded a number of holdings, either partially or in full, to crystalise gains generating total proceeds of £1.72 million. All realisations during the period were executed at levels in excess of the entry price, on the back of positive news flow including contract wins, acquisitive and operational progress. Market sentiment enabled the Manager to realise in full the holding in FireAngel Safety Technology, delivering a 6.7 times money multiple return over the life of the investment. At the end of May 2021, Vectura was the subject of a recommended cash offer from Carlyle Europe Partners, valuing the business at £958 million, which was a 27% premium to the previous day's closing price. The share price responded positively to the news, allowing the Manager to realise the holding in full generating a 1.6 times money multiple return over the life of the investment.

 

Notwithstanding the challenging market conditions during 2020, Anpario reported its best operating performance to date in the full year results to 31 December 2020. Revenue was 5% ahead of the prior year at £30.5 million, driven by sales growth in the Americas and Europe, as well as in the Chinese market which was helped by Anpario's regional subsidiaries and local legislation that banned the use of antibiotic growth promotion in animal feed. Gross profit improved by 9% to £15.8 million and adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) grew 16% to £6.6 million. The year-end cash position reflected the profit growth and increased by £2 million to £15.8 million. Further to this, the final dividend was raised by 12.5% to 9p per share.

 

In the half year to 30 November 2020, Avingtrans reported improving profits. Revenue was £51.4 million, with gross margin increasing to 30.9% and helped by a mix of restructuring and completion of non-repeat low margin orders at the company's acquired businesses. Revenue in engineered pumps and motors rose 17% to £26 million, with Hayward Tyler progressing well overall and Energy Steel seeing an improved performance. Adjusted EBITDA increased by 36.6% to £6.3 million, driven by a steady recovery at Booth and Energy Steel, both of which were acquired in 2019, and a better margin mix, stemming from cost reductions and higher project margins. Reported Profit Before Tax (PBT) came in at £1.4 million, with adjusted PBT (before restructuring costs) at £3.54 million. During the period, Booth was chosen by HS2 to produce cross-tunnel safety doors in a multi-year contract worth £36 million.

 

Concurrent Technologies reported results for the full year to 31 December 2020, which included revenue of £21.1 million, representing year on year growth of 9%, with gross profit increasing 12% to £11.4 million. The positive performance was driven by exports, which remained strong at 91% of revenue. EBITDA was flat, year on year, at £5 million and the cash position at the year end remained healthy at £11.8 million, with no borrowings. During the year, Concurrent maintained its long-term commitment to research and development by increasing spend by 10.8% to £3.9 million, and the dividend was increased to 2.55p per share. The new financial year started with a good order book, which has continued to grow through the first quarter of 2021, and Concurrent is confident that it can maintain this positive performance throughout the first half of the year.

 

Clinical stage innovative biotechnology company Destiny Pharma reported full year results for the year to 31 December 2020. A key highlight was the successful completion of a £10.4 million fundraise to acquire the global rights to NTCD-M3, a project targeting C. difficile gut infections, which is planned to start in mid-2022. In a further positive development, patient recruitment was successfully completed in December 2020 for its Phase IIb clinical trial of XF-73 nasal gel for the prevention of post-surgical infections such MRSA, which subsequently produced a highly significant reduction of the S. aureus bacteria in the nasal carriage in studied patients undergoing open heart surgery. Having identified a significant commercial opportunity for XF-73 in hospital settings, Destiny plans to discuss possible Phase III clinical study designs with regulatory bodies including the FDA. Destiny remains well funded with the year-end cash position of £9.7 million, which provides sufficient runway until Q2 2022.

 

In April 2021, Diurnal, the speciality pharmaceutical company that develops treatments for chronic hormonal disease, announced a conditional placing and subscription to raise up to £20 million at an issue price of 70p per share, together with an open offer raising a further £2 million. The offer was fully subscribed, and the proceeds will be used to progress Diurnal's pivotal Phase III studies of Efmody®, as a treatment for congenital adrenal hyperplasia (CAH), through to registration in the US, and the ongoing support of its earlier stage pipeline. In May 2021, following positive scientific and operational progress, the company announced that it had extended its exclusive licence agreement with Citrine, the speciality pharmaceutical company, to include the registration, distribution and marketing of Efmody® in China, Hong Kong, Taiwan and Macau. Under the deal, Diurnal will receive a non-refundable upfront payment of $1 million and $28.8 million in further cash payments upon achieving certain regulatory milestones and annual sales thresholds/milestones, as well as tiered royalties on sales.

 

During the period, Ideagen announced the acquisition of Qualtrax Inc, a fast-growing supplier of quality, health, safety and environmental compliance software, for a total net cash consideration of $14.9 million. Qualtrax has a good level of ARR which, at the time of acquisition, was $5.1 million with over 90% attributed to Software as a Service (SaaS). Ideagen forecast that Qualtrax will deliver adjusted EBITDA of $1.5 million in its first full financial year of ownership to 30 April 2022. Ideagen also released a year-end trading update for the period to 30 April 2021, which stated that revenue was ahead 16% of prior year at £65.6 million, with recurring revenues constituting 83% of total sales. Ideagen's transition to a SaaS model continued to drive organic growth, with ARR increasing 13% to £69.3 million, over the prior year. Additionally, Ideagen had secured 557 new customers during its financial year including KPMG, St. James's Place and Bank of Greece. Adjusted EBITDA was up 24% to £22.9 million. Cash generated from operations is expected to be more than 105% of adjusted EBITDA, with gross cash balance at period end of £9 million. Ideagen noted that it continues to have a solid position to fund further organic growth, with a robust balance sheet and debt facilities of up to £100 million.

 

In the year to 31 December 2020, Water Intelligence produced a positive set of results. Total revenue grew 17% to $37.9 million, statutory PBT rose 78% to $4.2 million, with total system sales surpassing $140 million, and adjusted PBT increasing 50% to $5.1 million. The 2020 full year results contributed to a compound annual growth rate (CAGR) from 2016-2020 of 33% in terms of revenue, and 53% for statutory PBT. The cash position at the year end was $6.8m. The trading update for the period up to 30 April 2021 reported that revenues were ahead by 47% at $15.6 million, with statutory PBT up 154% to $2.2 million. The company added that it was confident that it would be able to sustain growth through 2021 and beyond.

 

Liquidity Management

The Board and the Manager continue to operate an active liquidity management policy, with the objective of generating income from cash resources held prior to investment. The Manager has constructed a focused portfolio of private equity investment trust holdings and will continue to consider any other permitted investment options that have the potential to generate income prior to deployment in VCT qualifying companies.

 

New Investments

During the period, five new VCT qualifying private companies were added to the portfolio. These businesses operate in some of the UK's most dynamic market sectors, which have continued to experience growth despite the challenging conditions in the wider economy.

 

Adimo has developed a marketing technology platform for the fast-moving consumer goods (FMCG) sector, which is the world's largest advertising sector by spend. Adimo's solution gives FMCG advertisers a direct sales capability by connecting an advert or promotion to an online grocery basket and allowing a product to be added, either for purchase later or to be bought instantly through Adimo's Buy Now functionality. The software also provides brands with important data on customers' buying behaviour, to help support repeat purchases. Adimo has a strong blue chip client list that includes Coca-Cola, Danone and GSK. The VCT funding is being used to grow the revenue base and progress new client opportunities.

 

Atterley is an online fashion marketplace that is designed to give independent fashion retailers and brands access to a fully integrated ecommerce platform, and which offers a full range of services, including managing logistics, customer services and marketing support. The platform is aimed at the premium designer end of the market and offers their customers an extensive selection of emerging and undiscovered labels curated by high profile fashion buyers. The VCT funding is being used to expand the market presence in the US, make a number of specific hires, and develop further the technology platform.

 

Cardinality is a provider of a high volume data handling and analytics software platform, which enables clients to collate, manage and derive value from very large data sets. The business processes up to 15 billion lines of code per day, which is used to help its clients increase productivity, enhance marketing activities, improve fraud detection and identify customer spending habits or patterns. Activity is currently focused on the telecoms sector and its clients include Telefonica, Vodafone and Zain. The VCT funding is being used to expand into new target markets with an initial focus on the financial services sector.

 

eSalesHub is the developer of an artificial intelligence (AI) enabled sales analytics platform, which provides clients with real time insight into the sources of all inbound customer phone calls, allowing clients to optimise their media spend and strategy. eSalesHub is a Google Premier Partner and has over 200 clients including Barchester, Connells Estate Agents, Dyno (a division of British Gas) and Europcar. The VCT funding is being used to accelerate growth by expanding the team, further develop the SaaS model for larger enterprise clients, and provide working capital.

 

Horizon Technologies is a specialist manufacturer and supplier of airborne signals intelligence (SIGINT) systems for use in Intelligence, Surveillance and Reconnaissance applications. The core hardware solution FlyFish is currently in operation on numerous platforms worldwide, including daily search and rescue missions via NATO and FRONTEX in the Mediterranean as well as counter piracy operations off the coast of East Africa. The VCT funding is being used to support the market launch of the space-based Maritime Domain Awareness technology, Amber™, which has been developed in conjunction with the UK government. The technology builds on FlyFish's capabilities and will be added to commercial satellites to identify geolocation and classify maritime radars to help detect illegal activity such as piracy, smuggling, illegal fishing and terrorism.

 

In addition, six new AIM quoted investments have been added to the portfolio during the first half of the year:

 

Abingdon Health is a lateral flow diagnostics company that provides contract service solutions, such as product development, regulatory support, technology transfer and commercial manufacturing, to a global client base in healthcare and other sectors. Abingdon has developed the AbC-19TM Rapid Test for detecting COVID-19 antibodies, and also produces lateral flow tests covering other applications in areas such as infectious disease, oncology, animal health and environmental testing. Your Company participated in the £22 million fund raising, which completed in December 2020. The investment is being used to scale manufacturing to meet demand for AbC-19TM rapid lateral flow tests and allow Abingdon to establish a global commercial and operational footprint.

 

Crossword Cybersecurity is focused on the development and commercialisation of cyber security and risk management related software, based on university research, as well as cyber security consulting. The business goal is to build a portfolio of revenue generating cyber security products based on intellectual property. Your Company participated in the £1.6 million fundraising, which completed in February 2021. The investment is being used to increase sales and marketing resource, accelerate product development and provide additional working capital.

 

Evgen Pharma is a clinical stage drug development company that is focused on sulforaphane based medicines, which are a novel class of pharmaceuticals for the treatment of multiple diseases. The core technology is Sulforaedex®, which is a method for synthesising and stabilising the naturally occurring compound sulforaphane and producing novel proprietary analogues based on sulforaphane. Your Company participated in the £11 million fundraising, which completed in March 2021. The investment is being used to fund further preclinical work for metastatic breast cancer, to complete formulation and scale up manufacturing of Evgen's lead product SFX-01 and to fund operations through until mid-2023.

 

Incanthera is a specialist oncology company that is focused on innovative technologies in oncology and dermatology. The focus is to transform cancer therapeutics by limiting off-target toxicity (healthy tissue damage) in cancer treatment, which is a known and severe problem in the treatment of cancer. Incanthera identifies and develops innovative solutions where there are current clinical, commercially relevant unmet needs. The lead product is Sol, an innovative topical product for the treatment of solar keratosis and the prevention of skin cancers, which has achieved proof of concept. Your Company participated in the £1.1 million fund raising, which completed in March 2021. The investment is being used to progress discussions in respect of a potential commercial deal for Sol, and also provides cash runway until the second half of 2022.

 

Oncimmune is a leader in the field of early cancer detection. The company has developed a diagnostic test which is based on the presence of blood autoantibodies that work against specific tumours, such as lung cancer. The test has the potential to detect cancer up to four years earlier than traditional diagnostics such as X-rays or CT scans. Your Company participated in the £9 million fundraising, which completed in March 2021. The investment is being used to grow the pipeline of commercial prospects and increase operating capacity at the discovery research facility in Dortmund, Germany.

 

Polarean Imaging is an innovator in the medical imaging market, having developed equipment that enables existing MRI systems to achieve superior lung imaging by using hyperpolarised Xenon gas as an imaging agent. This provides a non-invasive and radiation-free functional imaging platform, which is more accurate and less harmful than current methods. Your company participated in the £25 million fundraising, which completed in April 2021. The investment is being used to support the ongoing clinical trial, build the commercial team, finance regulatory and medical costs and support the continued investment in research and development.

 

The following investments have been completed during the reporting period:

 

 

 

Investments

 

 

Date

 

 

Sector

Investment

cost

£'000

 

New unlisted

 

 

 

 

Atterley.com Holdings Limited

March 2021

Software & computer services

(consumer services)

613

www.atterley.com

Cardinality Limited

March 2021

Software & computer services

(data analytics)

796

www.cardinality.co.uk

eSales Hub Limited

March 2021

Software & computer services

(data analytics)

151

www.esaleshub.ai

Horizon Technologies Consultants Limited

May 2021

Aerospace & defence

796

www.horizontechnologies.eu

Rico Developments Limited (trading as Adimo)

February 2021

Software & computer services

(MarTech)

435

www.adimo.co

Rockar Retail Limited1

May 2021

Automotive

10

www.rockar.digital

Total new unlisted

 

 

2,801

 

 

Follow-on unlisted

 

 

 

 

GradTouch Limited

March 2021

Software & computer services (recruitment services)

167

www.gradtouch.com

Growth Capital Ventures Limited

March 2021

FinTech

31

www.growthcapitalventures.co.uk

Total follow-on unlisted

 

 

198

 

 

 

 

 

 

Total unlisted

 

 

2,999

 

 

New quoted

 

 

 

 

Abingdon Health PLC

December 2020

Pharmaceuticals & biotechnology

130

www.abingdonhealth.com

Crossword Cybersecurity PLC

February 2021

Software & computer services

(cyber security)

150

www.crosswordcybersecurity.com

Evgen Pharma PLC

March 2021

Pharmaceuticals & biotechnology

140

www.evgen.com

Incanthera PLC

March 2021

Pharmaceuticals & biotechnology

49

www.incanthera.com

Oncimmune PLC

March 2021

Pharmaceuticals & biotechnology

250

www.oncimmune.com

Polarean Imaging PLC

April 2021

Pharmaceuticals & biotechnology

246

www.polarean.com

Total new quoted

 

 

965

 

 

Follow-on quoted

Osirium Technologies PLC

 

 

April 2021

 

 

Software & computer service

(cyber security)

 

 

99

 

 

www.osirium.com

Total follow-on quoted

 

 

99

 

 

 

 

 

 

Total quoted

 

 

1,064

 

 

 

 

 

 

Total investments

 

 

4,063

 

 

 

1 Investment reflects the demerger of the retail business from the core Rockar technology platform.

 

At the period end, the portfolio stood at 118 unlisted and quoted investments, at a total cost of £38.23 million.

 

Realisations

In December 2020, the sale of peer-to-peer (P2P) lending platform Lending Works completed. Your Company first invested in April 2018, at a time when the P2P market was experiencing significant growth and Lending Works was positioned to become a credible challenger in this disruptive market. The outbreak of COVID-19, however, had a detrimental impact on consumer appetite for lending, and the Manager made the decision to exit from the investment. Following a formal sales process, an offer for the business was accepted from private asset manager, Intrivia Capital, with the sale completing in December 2020. The exit generated a total return of 0.92 times cost over the life of the investment.

 

The table below gives details of all realisations achieved during the reporting period:

 

 

 

 

 

Sales

 

 

 

Year first invested

 

 

 

Complete/ partial exit

Cost of shares disposed of

£'000

Value at

30 November

2020

£'000

 

 

Sales proceeds

£'000

 

 

Realised gain/(loss)

£'000

Gain/(loss) over

30 November 2020 value

£'000

Unlisted

 

 

 

 

 

 

 

ADC Biotechnology Limited

2017

Complete

644

97

173

(471)

76

Cambridge Sensors Limited1

2002

Complete

1,184

342

339

(845)

(3)

Lending Works Limited

2018

Complete

349

296

320

(29)

24

Maven Co-invest Fletcher

2013

Complete

-

-

20

20

20

Limited Partnership2

 

 

 

 

 

 

 

Others

 

 

-

-

15

15

15

Total unlisted

 

 

2,177

735

867

(1,310)

132

 

Quoted

 

 

 

 

 

 

 

Access Intelligence PLC

2010

Partial

91

163

160

69

(3)

C4X Discovery Holdings PLC

2019

Partial

7

9

10

3

1

Evgen Pharma PLC

2021

Partial

24

-

26

2

-

FireAngel Safety Technology

2008

Complete

36

15

16

(20)

1

Group PLC

 

 

 

 

 

 

 

Ideagen PLC

2005

Partial

19

546

728

709

182

Vectura PLC

2001

Complete

75

160

230

155

70

Water Intelligence PLC

2009

Partial

51

375

542

491

167

Others

 

 

2

-

3

1

-

Total quoted

 

 

305

1,268

1,715

1,410

418

 

 

 

 

 

 

 

 

Total sales

 

 

2,482

2,003

2,582

100

550

 

1 Full exit from pre-2010 inherited legacy holding.

2 Interim recovery proceeds.

 

During the period, one private company was struck off the Register of Companies, resulting in a realised loss of £271,000 (cost £271,000). This had no effect on the NAV of the Company as a full provision had been made against the value of the holding in a previous period.

 

Material Developments Since the Period End

Since 31 May 2021, two new private company holdings have been added to the portfolio.

 

Guru Systems is a supplier of business-to-business Internet of Things hardware, software and analytics solutions that help to improve the performance and cost-effectiveness of heating systems. Guru's carbon saving monitoring technology is initially focused on heat networks, which generate and supply heat centrally to consumers via a network of underground hot water pipes, avoiding the need for individual boilers or electric heaters in every building. Guru's solutions have the potential to improve each stage of a heat networks project, resulting in significant improvements in performance. This is an attractive growth market, with strong ESG credentials, which is heavily supported by the Government's decarbonisation strategy as part of the Net Zero agenda. The VCT funding is being used to invest in sales and marketing, to launch the latest products and to prepare the business for overseas expansion.

 

Snappy Shopper provides local convenience stores with the technology to set-up home delivery services at a minimal cost. The key advantage of the proposition is that it provides delivery to the customer within 30-60 minutes, thereby providing true convenience whilst also significantly increasing average basket spend. A large number of convenience stores do not currently have a home delivery service, which presents a significant market opportunity. Snappy has experienced rapid growth over the past year and has ambitious targets to continue its store roll-out programme. The business also includes Hungrrr, a white-label online and app food ordering system for the hospitality sector that has also experienced strong growth and has a client list that includes Brewdog, Hilton, Holiday Inn and UEFA Champions League. The VCT funding is being used to expand market share, support the technology development and to scale the team in line with growth.

 

In July 2021, the conditional sale of Mojo Mortgages completed, subject to FCA approval. Your Company first invested in Mojo in 2019, supporting an ambitious management team to develop its disruptive mortgage broking technology platform. Mojo's solution provides an innovative hybrid of online and advised services, capable of managing the full process from mortgage product price comparison through to the mortgage application and completion. During the period under review, an offer to acquire the business was received from RVU, which is part of the Zoopla Property Group that owns a number of consumer finance and comparison sites such as Confused.com, Uswitch and Zoopla. The sale completed post the period end, although it is subject to FCA approval, and will generate a total return of up to 1.8 times cost over the life of the investment.

 

In July 2021, GENinCode, the developer of patented risk assessment products for the prevention of cardiovascular disease, successfully floated on AIM, raising £17 million and achieving a post listing market capitalisation of £42 million. Your Company invested in GENinCode, in July 2020 and, after early scientific and clinical success in validating its genomic technology and products, the objective to float on AIM was identified as a strategic target that would enable the business to fulfil its international growth ambition and enhance product development. Maven's dedicated AIM team played a key role in assisting the management team with this transaction.

 

Outlook

Despite the recent challenges in the wider economy, your Company has made positive progress during the first half of the financial year, and remains well positioned to continue to deliver its core strategic investment objective. The Manager is encouraged by both the growth in the number of portfolio holdings and also the underlying performance, where the majority of investee companies continue to make good commercial progress and grow Shareholder value. The Manager remain cautiously optimistic that there will be a progressive economic recovery once the remaining COVID-19 restrictions are lifted in the UK and in key export markets. 

 

More generally, the UK is currently experiencing good levels of M&A activity post Brexit where improved certainty has returned to markets, including the re-emergence of overseas investors and acquirers, notably from the US. These factors are now positively affecting private company markets and the Manager considers that this augurs well for the immediate prospects for your Company against a backdrop of continuing strong levels of new investment activity. 

 

Maven Capital Partners UK LLP

Manager

 

10 August 2021

 

 

 

Investment Portfolio Summary

 

As at 31 May 2021

 

Investment

 

 

Valuation

£'000

 

 

Cost

£'000

 

 

% of total assets

 

 

% of

equity held

% of equity held by other clients1

Unlisted

 

 

 

 

 

Life's Great Group Limited

1,380

820

2.1

9.9

35.6

(trading as Mojo Mortgages)

 

 

 

 

 

Relative Insight Limited

1,080

600

1.7

3.2

26.1

Rockar 2016 Limited (trading as Rockar)

1,072

980

1.7

5.2

16.4

Horizon Ceremonies Limited (trading as Horizon

990

660

1.6

3.6

49.1

Cremation)

 

 

 

 

 

Bright Network (UK) Limited

971

940

1.5

8.4

29.5

The GP Service (UK) Limited

892

860

1.4

10.3

41.0

e.fundamentals (Group) Limited

805

500

1.2

1.6

9.2

Horizon Technologies Consultants Limited

796

796

1.2

5.5

11.7

Cardinality Limited

796

796

1.2

7.9

17.0

Delio Limited

760

400

1.1

2.7

10.8

CB Technology Group Limited

759

521

1.1

10.6

68.3

Glacier Energy Services Holdings Limited

643

643

0.9

2.5

25.2

Nano Interactive Group Limited

625

625

0.9

3.7

11.2

Atterley.com Holdings Limited

613

613

0.9

7.6

10.0

Contego Solutions Limited (trading as NorthRow)

598

598

0.9

4.9

27.3

GradTouch Limited

567

567

0.8

8.5

34.7

CatTech International Limited

557

299

0.8

2.9

27.2

Push Technology Limited

525

525

0.8

2.8

8.5

Precursive Limited

500

500

0.7

4.3

17.3

Flow UK Holdings Limited

498

498

0.7

6.0

29.0

QikServe Limited

494

494

0.7

2.2

13.6

Whiterock Group Limited

490

321

0.7

5.2

24.8

Vodat Communications Group Limited

476

264

0.7

2.0

24.9

Servoca PLC2

470

613

0.7

3.0

-

CODILINK UK Limited (trading as Coniq)

450

450

0.7

1.3

3.6

GENinCode UK Limited

440

200

0.6

2.2

14.4

RMEC Group Limited

439

308

0.6

2.0

48.1

Filtered Technologies Limited

435

400

0.6

4.3

22.3

Rico Developments Limited (trading as Adimo)

435

435

0.6

3.3

6.4

HiveHR Limited

411

350

0.6

7.1

31.8

BioAscent Discovery Limited

392

174

0.6

4.4

35.6

Hublsoft Group Limited

375

300

0.6

4.7

26.5

 

 

Investment Portfolio Summary (Continued)

 

As At 31 May 2021

 

 

 

 

Investment

 

 

Valuation

£'000

 

 

Cost

£'000

 

 

% of total assets

 

 

% of

equity held

% of equity held by other clients1

Unlisted

 

 

 

 

 

HCS Control Systems Group Limited

373

373

0.5

3.0

33.5

WaterBear Education Limited

348

245

0.5

5.1

34.1

eSafe Global Limited

346

257

0.5

7.8

43.7

MirrorWeb Limited

306

150

0.4

2.1

34.8

ClearStar Inc2

306

435

0.4

2.1

-

Boiler Plan (UK) Limited

302

400

0.4

8.2

48.3

Quorum Cyber Security Limited

300

150

0.4

2.6

18.4

RevLifter Limited

300

300

0.4

3.6

14.3

Ensco 969 Limited (trading as DPP)

292

515

0.4

2.2

32.3

Growth Capital Ventures Limited

275

264

0.4

5.1

40.3

ebb3 Limited

264

206

0.4

4.9

53.7

Curo Compensation Limited

262

262

0.4

2.0

17.0

Optoscribe Limited

187

187

0.3

1.5

8.1

eSales Hub Limited

150

150

0.2

1.7

16.9

Maven Co-invest Endeavour Limited Partnership

141

1

0.2

5.9

94.1

(invested in Global Risk Partners)

 

 

 

 

 

The Algorithm People Limited

100

100

0.1

3.3

22.7

ISN Solutions Group Limited

98

250

0.1

3.6

51.4

AVID Technology Group Limited

91

364

0.1

1.5

8.4

R&M Engineering Group Limited

80

357

0.1

4.0

66.6

Intilery.com Limited

75

75

0.1

0.8

43.2

Honcho Markets Limited

65

64

0.1

1.2

23.5

Shortbite Limited (trading as DigitalBridge)

64

257

0.1

1.1

30.5

Fathom Systems Group Limited

64

593

0.1

6.7

53.3

Altra Consultants Limited

50

100

0.1

1.7

58.3

LightwaveRF PLC2

40

74

0.1

0.9

0.9

Other unlisted investments

28

1,802

 

 

 

Total unlisted

25,640

24,981

37.7

 

 

 

 

Investment Portfolio Summary (Continued)

 

As At 31 May 2021

 

Investment

 

 

Valuation

£'000

 

 

Cost

£'000

 

 

% of total assets

 

 

% of

equity held

% of equity held by other clients1

Quoted

 

 

 

 

 

Ideagen PLC

4,589

131

6.8

0.7

0.2

Water Intelligence PLC

2,449

202

3.6

1.7

-

Access Intelligence PLC

717

271

1.1

0.7

0.1

Concurrent Technologies PLC

444

161

0.7

0.7

-

K3 Business Technology Group PLC

391

238

0.6

0.6

-

Polarean Imaging PLC

373

246

0.5

0.2

0.5

Vianet Group PLC

345

405

0.5

1.2

0.3

Avingtrans PLC

304

54

0.4

0.3

-

Renalytix AI PLC

299

-

0.4

-

-

Oncimmune Holdings PLC

285

250

0.4

0.2

0.4

Crossword Cybersecurity PLC

265

150

0.4

1.0

1.0

Anpario PLC

262

57

0.4

0.2

-

ReNeuron Group PLC

257

150

0.4

0.4

1.7

Netcall PLC

231

26

0.3

0.2

-

Destiny Pharma PLC

208

100

0.3

0.3

1.5

Avacta Group PLC

206

13

0.3

-

0.1

Synectics PLC

179

308

0.3

0.8

-

DeepMatter Group PLC

161

201

0.2

0.9

1.5

Osirium Technologies PLC

154

199

0.2

3.1

5.6

Eden Research PLC

152

83

0.2

0.4

1.0

Diurnal Group PLC

133

62

0.2

0.2

0.6

Evgen Pharma PLC

127

116

0.2

0.5

0.5

C4X Discovery Holdings PLC

113

40

0.2

0.1

0.9

Seeen PLC

107

100

0.2

0.4

1.0

Croma Security Solutions Group PLC

105

433

0.2

0.9

-

RUA Life Sciences PLC

99

229

0.1

0.3

1.3

Intelligent Ultrasound Group PLC

84

51

0.1

0.2

1.9

Abingdon Health PLC

73

128

0.1

0.1

0.1

Trackwise Designs PLC

72

25

0.1

0.1

0.6

Incanthera PLC

45

49

0.1

0.6

0.6

Vertu Motors PLC

36

50

0.1

-

-

Merit Group PLC (formerly Dods Group PLC)

34

450

-

-

-

Transense Technologies PLC

26

1,188

-

0.3

-

Other quoted investments

49

4,689

 

 

 

Total quoted

13,374

10,855

19.6

 

 

 

 

 

Investment Portfolio Summary (Continued)

 

As At 31 May 2021

 

 

 

 

Investment

 

 

Valuation

£'000

 

 

Cost

£'000

 

 

% of total assets

 

 

% of

equity held

% of equity held by other clients1

Private equity investment trusts

 

 

 

 

 

HgCapital Trust PLC

476

315

0.6

0.3

1.0

HarbourVest Global Private Equity Limited

425

310

0.6

-

0.1

Princess Private Equity Holding Limited

402

308

0.6

-

0.2

ICG Enterprise Trust PLC

391

324

0.6

-

0.1

BMO Private Equity Trust PLC (formerly F&C

386

342

0.6

0.1

0.3

Apax Global Alpha Limited

379

289

0.6

-

0.1

Standard Life Private Equity Trust PLC

346

266

0.5

-

0.1

Pantheon International PLC

290

236

0.4

-

0.1

Total private equity investment trusts

3,095

2,390

4.5

 

 

 

 

 

 

 

 

Total investments

42,109

38,226

61.8

 

 

 

1 Other clients of Maven Capital Partners UK LLP.

2 This company delisted from AIM in a previous period.

 

 

Income Statement

 

For the six months ended 31 May 2021

 

 

Six months ended

31 May 2021

(unaudited)

Six months ended

31 May 2020

(unaudited)

Year ended

30 November 2020

(audited)

 

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Revenue

£'000

Capital

£'000

Total

£'000

Gains on investments

-

6,807

6,807

-

(1,571)

(1,571)

-

1,442

1,442

Income from investments

200

-

200

278

-

278

473

-

473

Other income

1

-

1

20

-

20

28

-

28

Investment management fees

(157)

(472)

(629)

(105)

(314)

(419)

(239)

(718)

(957)

Other expenses

(135)

-

(135)

(150)

-

(150)

(330)

-

(330)

Net return on ordinary activities before taxation

(91)

6,335

6,244

43

(1,885)

(1,842)

(68)

724

656

 

Tax on ordinary activities

 

-

 

-

 

-

 

-

 

-

 

-

 

33

 

(33)

 

-

Return attributable to Equity Shareholders

(91)

6,335

6,244

43

(1,885)

(1,842)

(35)

691

656

 

Earnings per share (pence)

 

(0.06)

 

4.37

 

4.30

 

0.03

 

(1.50)

 

(1.47)

 

(0.03)

 

0.55

 

0.52

           

 

All gains and losses are recognised in the Income Statement.

 

All items in the above statement are derived from continuing operations. The Company has only one class of business and one reportable segment, the results of which are set out in the Income Statement and Balance Sheet. The Company derives its income from investments made in shares, securities and bank deposits.

 

There are no potentially dilutive capital instruments in issue and therefore no diluted earnings per share figures are relevant. The basic and diluted earnings per share are therefore identical.

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Statement Of Changes In Equity

 

Six months ended 31 May 2021

 

 

Non Distributable Reserves

Distributable Reserves

 

Six months ended

31 May 2021

(unaudited)

Share capital

£'000

Share premium account

£'000

Capital

redemption

reserve

£'000

Capital reserve unrealised

£'000

Capital reserve realised

£'000

Special distributable reserve

£'000

Revenue reserve

£'000

Total

£'000

At 30 November 2020

12,405

21

218

(3,095)

1,734

35,087

(1,234)

45,136

Net return

-

-

-

6,978

(171)

(472)

(91)

6,244

Dividends paid

-

-

-

-

-

(1,926)

-

(1,926)

Repurchase and cancellation of shares

(190)

-

190

-

-

(655)

-

(655)

Net proceeds of share issue

5,381

13,667

-

-

-

-

-

19,048

Net proceeds of DIS issue

58

143

-

-

-

-

-

201

At 31 May 2021

17,654

13,831

408

3,883

1,563

32,034

(1,325)

68,048

 

 

Six months ended

31 May 2020 (unaudited)

Non Distributable Reserves

Distributable Reserves

 

Share capital

£'000

Share premium account

£'000

Capital

redemption

reserve

£'000

Capital reserve unrealised

£'000

Capital reserve realised

£'000

Special distributable reserve

£'000

Revenue reserve

£'000

Total

£'000

At 30 November 2019

12,608

23,180

3,955

(2,803)

(25,602)

36,862

(1,076)

47,124

Net return

-

-

-

(2,448)

563

-

43

(1,842)

Cancellation of share premium account

-

(23,180)

-

-

-

23,180

-

-

Cancellation of capital redemption reserve

-

-

(3,955)

-

-

3,955

-

-

Share premium cancellation costs

-

(10)

-

-

-

-

-

(10)

Dividends paid

-

-

-

-

-

(1,258)

(123)

(1,381)

Repurchase and cancellation of shares

(100)

-

100

-

-

(310)

-

(310)

At 31 May 2020

12,508

(10)

100

(5,251)

(25,039)

62,429

(1,156)

43,581

 

 

 

Non Distributable Reserves

Distributable Reserves

 

Year ended

30 November 2020

(audited)

Share capital

£'000

Share premium account

£'000

Capital

redemption

reserve

£'000

Capital reserve unrealised

£'000

Capital reserve realised

£'000

Special distributable reserve

£'000

Revenue reserve

£'000

Total

£'000

At 30 November 2019

12,608

23,180

3,955

(2,803)

-

11,260

(1,076)

47,124

Net return

-

-

-

(292)

1,734

(751)

(35)

656

Cancellation of share premium account

-

(23,180)

-

-

-

23,180

-

-

Cancellation of capital redemption reserve

-

-

(3,955)

-

-

3,955

-

-

Share premium cancellation costs

-

(10)

-

-

-

-

-

(10)

Dividends paid

-

-

-

-

-

(1,882)

(123)

(2,005)

Repurchase and cancellation of shares

(218)

-

218

-

-

(675)

-

(675)

Net proceeds of DIS issue

15

31

-

-

-

-

-

46

At 30 November 2020

12,405

21

218

(3,095)

1,734

35,087

(1,234)

45,136

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Balance Sheet

 

As at 31 May 2021

 

 

31 May 2021

(unaudited)

£'000

31 May 2020

(unaudited)

£'000

30 November 2020

(audited)

£'000

Fixed assets

 

 

 

Investments at fair value through profit or loss

42,109

30,238

33,821

 

Current assets

 

 

 

Debtors

367

320

242

Cash

25,829

13,084

11,543

 

26,196

13,404

11,785

Creditors

 

 

 

Amounts falling due within one year

(257)

(61)

(470)

Net current assets

25,939

13,343

11,315

Net assets

68,048

43,581

45,136

 

Capital and reserves

 

 

 

Called up share capital

17,654

12,508

12,405

Share premium account

13,831

(10)

21

Capital redemption reserve

408

100

218

Capital reserve - unrealised

3,883

(5,251)

(3,095)

Capital reserve - realised

1,563

(26,297)

1,734

Special distributable reserve

32,034

63,687

35,087

Revenue reserve

(1,325)

(1,156)

(1,234)

Net assets attributable to Ordinary Shareholders

68,048

43,581

45,136

Net asset value per Ordinary Share (pence)

 

38.54

 

34.84

 

36.38

 

The Financial Statements were approved and authorised for issue by the Board of Directors on 10 August 2021 and were signed on its behalf by:

 

 

Graham Miller

Chairman

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Cash Flow Statement

 

For the six months ended 31 May 2021

 

 

Six months ended

31 May 2021

(unaudited)

£'000

Six months ended

31 May 2020

(unaudited)

£'000

Year ended

30 November 2020

(audited)

£'000

Net cash flows from operating activities

(605)

(416)

(720)

Cash flows from investing activities

 

 

 

Purchase of investments

(4,213)

(5,002)

(7,196)

Sale of investments

2,516

1,729

3,549

Net cash flows from investing activities

(1,697)

(3,273)

(3,647)

 

Cash flows from financing activities

 

 

 

Equity dividends paid

(1,926)

(1,381)

(2,005)

Issue of Ordinary Shares

19,249

-

46

Share premium cancellation costs

-

(10)

(10)

Repurchase of Ordinary Shares

(735)

(484)

(769)

Net cash flows from financing activities

16,588

(1,875)

(2,738)

 

 

 

 

Net increase / (decrease) in cash

14,286

(5,564)

(7,105)

 

Cash at beginning of period

 

11,543

 

18,648

 

18,648

Cash at end of period

25,829

13,084

11,543

 

 

The accompanying Notes are an integral part of the Financial Statements.

 

 

Notes To The Financial Statements

 

1. Accounting Policies

 

The financial information for the six months ended 31 May 2021 and the six months ended 31 May 2020 comprises non- statutory accounts within the meaning of S435 of the Companies Act 2006. The financial information contained in this report has been prepared on the basis of the accounting policies set out in the Annual Report and Financial Statements for the year ended 30 November 2020, which have been filed at Companies House and which contained an Auditors' Report which was not qualified and did not contain a statement under S498 (2) or S498 (3) of the Companies Act 2006.

 

2. Reserves

 

Share premium account

 

The share premium account represents the premium above nominal value received by the Company on issuing shares net of issue costs. This reserve is non-distributable.

 

Capital redemption reserve

 

The nominal value of shares repurchased and cancelled is represented in the capital redemption reserve. This reserve is non-distributable.

 

Capital reserve - unrealised

 

Increases and decreases in the fair value of investments are recognised in the Income Statement and are then transferred to the capital reserve unrealised account. This reserve is non-distributable.

 

Capital reserve - realised

 

Gains or losses on investments realised in the year that have been recognised in the Income Statement are transferred to the capital reserve realised account on disposal. Furthermore, any prior unrealised gains or losses on such investments are transferred from the capital reserve unrealised account to the capital reserve realised account on disposal. This reserve is distributable.

 

Special distributable reserve

 

The total cost to the Company of the repurchase and cancellation of shares is represented in the special distributable reserve account. The special distributable reserve also represents capital dividends, capital investment management fees and the tax effect of capital items. This reserve is distributable.

 

Revenue reserve

 

The revenue reserve represents accumulated profits retained by the Company that have not been distributed to shareholders as a dividend. This reserve is distributable.

 

3. Return per Ordinary Share

 

Six months ended 31 May 2021

The returns per share have been based on the following figures:

Weighted average number of Ordinary Shares

 

 

Revenue return

Capital return

 

145,069,401

 

 

(£91,000)

£6,335,000

Total return

£6,244,000

 

Directors' Responsibility Statement

 

The Directors confirm that, to the best of their knowledge:

 

• the Financial Statements for the six months ended 31 May 2021 have been prepared in accordance with FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland;

 

• the Interim Management Report, comprising the Chairman's Statement and the Investment Manager's Interim Review, includes a fair review of the information required by DTR 4.2.7R in relation to the indication of important events during the first six months, and of the principal and emerging risks and uncertainties facing the Company during the second six months, of the year ending 30 November 2021; and

 

• the Interim Management Report includes adequate disclosure of the information required by DTR 4.2.8R in relation to related party transactions and any changes therein.

 

Other information

 

The NAV per Ordinary Share has been calculated using the number of Ordinary Shares in issue at 31 May 2021, which was 176,545,809. A summary of investment changes for the six months under review and an investment portfolio summary as at 31 May 2021 are included above. A full copy of the Interim Report and Financial Statements will be printed and issued to Shareholders in due course. Copies of this announcement will be available to the public at the office of Maven Capital Partners UK LLP, Kintyre House, 205 West George Street, Glasgow, G2 2LW; at the registered office of the Company at 1-2 Royal Exchange Buildings, London, EC3V 3LF; and on the Company's website at: www.mavencp.com/migvct5.

 

Neither the content of the Company's website nor the contents of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into, or forms part of, this announcement.

 

 

On behalf of the Board

Maven Capital Partners UK LLP

Secretary

 

10 August 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR SFAFISEFSEFA
Date   Source Headline
3rd May 20249:28 amRNSIssue of Equity
1st May 202410:10 amRNSIssue of Equity
26th Apr 20242:44 pmRNSUnaudited NAV - Dividend Investment Scheme
23rd Apr 20242:27 pmRNSResult of AGM
19th Apr 202412:17 pmRNSIssue of Supplementary Prospectus
5th Apr 20243:49 pmRNSIssue of Equity
27th Mar 202410:31 amRNSIssue of Equity
22nd Mar 20244:25 pmRNSStatement re Offer for Subscription
22nd Mar 202410:14 amRNSIssue of Supplementary Prospectus
20th Mar 20243:48 pmRNSUnaudited Net Asset Value
8th Mar 20242:57 pmRNSAnnual Financial Report
15th Feb 20244:45 pmRNSTransaction in Own Shares
8th Feb 202410:33 amRNSDirector/PDMR Shareholding
8th Feb 202410:12 amRNSIssue of Equity
7th Feb 20243:09 pmRNSDividend Declaration
19th Dec 20233:28 pmRNSIssue of Equity
18th Dec 20235:24 pmRNSUnaudited Net Asset Value
9th Nov 20233:51 pmRNSResult of General Meeting
20th Oct 20234:13 pmRNSTransaction in Own Shares
13th Oct 20234:56 pmRNSPublication of a Prospectus
4th Oct 20234:03 pmRNSNet Asset Value(s)
29th Aug 20239:15 amRNSDirectorate Change
24th Jul 202311:16 amRNSHalf-year Report
21st Jul 20234:43 pmRNSTransaction in Own Shares
21st Jul 20239:48 amRNSIssue of Equity
17th Jul 202310:57 amRNSNet Asset Value - Dividend Investment Scheme
11th Jul 20234:47 pmRNSNet Asset Value
6th Jul 20234:01 pmRNSStatement re Intended Offers for Subscription
14th Jun 202310:33 amRNSDividend Declaration
2nd Jun 20239:48 amRNSIssue of Equity
5th May 202310:23 amRNSIssue of Equity - Dividend Investment Scheme
27th Apr 20233:57 pmRNSTransaction in Own Shares
27th Apr 20231:04 pmRNSIssue of Supplementary Prospectus
26th Apr 202311:39 amRNSNet Asset Value - Dividend Investment Scheme
25th Apr 20233:14 pmRNSNet Asset Value(s)
25th Apr 202312:50 pmRNSResult of AGM
5th Apr 202312:32 pmRNSIssue of Equity
29th Mar 20232:19 pmRNSIssue of Supplementary Prospectus
23rd Mar 20235:18 pmRNSAnnual Financial Report
3rd Mar 20239:56 amRNSIssue of Equity
21st Feb 20234:44 pmRNSTransaction in Own Shares
8th Feb 202310:24 amRNSDirector/PDMR Shareholding
8th Feb 20239:48 amRNSIssue of Equity
1st Feb 20233:25 pmRNSUnaudited NAV and Proposed Final Dividend
9th Nov 20223:02 pmRNSResult of General Meeting
4th Nov 20223:25 pmRNSTransaction in Own Shares
26th Oct 20223:53 pmRNSTransaction in Own Shares
7th Oct 20224:28 pmRNSPublication of a Prospectus
4th Oct 20223:30 pmRNSChange of Auditor
4th Oct 20221:35 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.